GSK2340272A

**GSK2340272A** is GSK's AS03-adjuvanted, monovalent pandemic influenza A H1N1 vaccine, marketed in Europe as **Pandemrix**. It contains inactivated split-virion antigen derived from the A/California/7/2009 H1N1v-like strain and is formulated with the AS03 oil-in-water adjuvant system to enhance antigen-specific immune responses. The vaccine was administered by intramuscular injection and studied in adults, elderly people, children, and infants during the 2009 H1N1 pandemic. Pandemrix received EU authorization for prophylaxis of influenza caused by A H1N1v 2009, but its EU marketing authorization expired on August 13, 2015 after GSK did not seek renewal because of lack of demand. ([clinicaltrialsregister.eu](https://www.clinicaltrialsregister.eu/ctr-search/rest/download/result/attachment/2009-016078-33/1/13718))

Brand names

Pandemrix

Other names

GSK2340272GSK-2340272GSK 2340272pandemic influenza vaccine H1N1influenza vaccine H1N1 split virion inactivated adjuvanted